Market cap
$51 Mln
Revenue (TTM)
$2 Mln
P/E Ratio
--
P/B Ratio
1.4
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 105.59 | -- | -68.40 | -75.65 | -42.50 |
| EBIT | -- | -- | 49.77 | 21.94 | 12.38 |
| Net Profit | 123.01 | 123.07 | -126.13 | 22.84 | 12.85 |
| EPS | 122.86 | 120.92 | -121.20 | 23.94 | 13.92 |
| Book Value | -- | -- | 212.86 | 42.52 | -33.46 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| 286.69 | -490.23 | -1,436.22 | 721.93 | -- |
| Net Margin
| -- | -1,341.60 | -1,192.94 | -- | -- |
| Return on equity
| 543.53 | 247.23 | -57.05 | 19.64 | 943.43 |
| Return on Capital
| -59.21 | -70.40 | -- | 4.90 | -113.03 |
| Return on Assets
| -28.96 | -35.35 | -15.16 | 4.10 | -58.82 |
| Debt to Equity (x)
| -- | -- | 0.00 | 1.88 | 6.65 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Seres Therapeutics (MCRB)
|
--
|
4.90
|
-113.03
|
-69.49
|
-141.30
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-57.05
Lower than Peers by 16.65
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Seres Therapeutics (MCRB)
|
-57.05
|
19.64
|
943.43
|
667.53
|
-351.62
|
|
Peer Median
|
-40.40
|
--
|
--
|
--
|
--
|
ROA
-15.16
Higher than Peers by 15.82
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Seres Therapeutics (MCRB)
|
-15.16
|
4.10
|
-58.82
|
-32.15
|
-71.10
|
|
Peer Median
|
-30.98
|
--
|
--
|
--
|
--
|
EBIT Margin
-1,436.22
Lower than Peers by 1,352.60
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Seres Therapeutics (MCRB)
|
-1,436.22
|
721.93
|
--
|
-148.55
|
-2,491.04
|
|
Peer Median
|
-83.62
|
--
|
--
|
--
|
--
|
Net Margin
-1,192.94
Lower than Peers by 1,100.27
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Seres Therapeutics (MCRB)
|
-1,192.94
|
721.93
|
--
|
-90.02
|
-2,638.51
|
|
Peer Median
|
-92.67
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
Lower than Peers by 0.00
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Seres Therapeutics (MCRB)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
Revenue Growth
-68.40
Lower than Peers by 122.35
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Seres Therapeutics (MCRB)
|
-68.40
|
--
|
-1.00
|
16.72
|
-0.95
|
|
Peer Median
|
53.95
|
--
|
--
|
--
|
--
|
EBIT Growth
49.77
Higher than Peers by 50.57
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Seres Therapeutics (MCRB)
|
49.77
|
104.53
|
32.98
|
-5.69
|
-183.34
|
|
Peer Median
|
-0.80
|
--
|
--
|
--
|
--
|
Net Profit Growth
-126.13
Lower than Peers by 118.83
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Seres Therapeutics (MCRB)
|
-126.13
|
103.89
|
-28.88
|
54.54
|
-281.46
|
|
Peer Median
|
-7.30
|
--
|
--
|
--
|
--
|
EPS Growth
-121.20
Lower than Peers by 135.85
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Seres Therapeutics (MCRB)
|
-121.20
|
1.04
|
0.04
|
0.56
|
-1.80
|
|
Peer Median
|
14.65
|
--
|
--
|
--
|
--
|
Book Value Growth
-4.98
Higher than Peers by 5.19
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Seres Therapeutics (MCRB)
|
-4.98
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.18
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Seres Therapeutics (MCRB)
|
--
|
1.88
|
6.65
|
-4.43
|
15.08
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.34
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Seres Therapeutics (MCRB)
|
0.34
|
0.23
|
0.63
|
-0.12
|
0.38
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
2.11
Lower than Peers by 3.70
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Seres Therapeutics (MCRB)
|
2.11
|
2.56
|
0.94
|
1.78
|
2.28
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
2.11
Lower than Peers by 3.58
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Seres Therapeutics (MCRB)
|
2.11
|
--
|
--
|
1.48
|
2.28
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Seres Therapeutics (MCRB)
|
--
|
--
|
--
|
-14.24
|
-29.50
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
1,342.22
Higher than Peers by 1,323.08
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Seres Therapeutics (MCRB)
|
1,342.22
|
45.63
|
--
|
6.87
|
--
|
|
Peer Median
|
19.14
|
--
|
--
|
--
|
--
|
Asset Turnover
0.01
Lower than Peers by 0.05
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Seres Therapeutics (MCRB)
|
0.01
|
0.01
|
--
|
0.36
|
0.02
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Seres Therapeutics (MCRB)
|
--
|
1,183.01
|
--
|
25.08
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Seres Therapeutics (MCRB)
|
--
|
--
|
3,065.85
|
279.94
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Seres Therapeutics (MCRB)
|
--
|
254.56
|
399.17
|
199.05
|
5,670.65
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Seres Therapeutics (MCRB)
|
--
|
--
|
--
|
105.96
|
-5,670.65
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Seres Therapeutics (MCRB)
|
--
|
23.17
|
-0.05
|
-0.08
|
-0.14
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
1.44
Lower than Peers by 3.74
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Seres Therapeutics (MCRB)
|
1.44
|
2.98
|
0.52
|
-0.20
|
3.25
|
|
Peer Median
|
5.18
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Seres Therapeutics (MCRB)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
3.65
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Seres Therapeutics (MCRB)
|
3.65
|
17.21
|
-0.57
|
-0.44
|
-0.10
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
51
Lower than Peers by 95
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Seres Therapeutics (MCRB)
|
51
|
--
|
--
|
--
|
--
|
|
Peer Median
|
146
|
--
|
--
|
--
|
--
|